A citation-based method for searching scientific literature

Andrea DeCensi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Silvia Caviglia, Franca Avino, Laura Cortesi, Cristiana Taverniti, Maria Grazia Pacquola, Fabio Falcini, Marcella Gulisano, Maria Digennaro, Anna Cariello, Katia Cagossi, Graziella Pinotti, Matteo Lazzeroni, Davide Serrano, Daniela Branchi, Sara Campora, Marilena Petrera, Tania Buttiron Webber, Luca Boni, Bernardo Bonanni. J Clin Oncol 2019
Times Cited: 67







List of co-cited articles
503 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
237
29

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
570
23

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
Kala Visvanathan, Carol J Fabian, Elissa Bantug, Abenaa M Brewster, Nancy E Davidson, Andrea DeCensi, Justin D Floyd, Judy E Garber, Erin W Hofstatter, Seema A Khan,[...]. J Clin Oncol 2019
60
26

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
132
22

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
347
22

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
20

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell. Lancet 2020
45
31

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
842
19

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
392
16

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
D Craig Allred, Stewart J Anderson, Soonmyung Paik, D Lawrence Wickerham, Iris D Nagtegaal, Sandra M Swain, Elefetherios P Mamounas, Thomas B Julian, Charles E Geyer, Joseph P Costantino,[...]. J Clin Oncol 2012
193
14

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George. Lancet Oncol 2011
320
14

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
14

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Samuel George Smith, Ivana Sestak, Anthony Howell, John Forbes, Jack Cuzick. J Clin Oncol 2017
28
32

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
13

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
274
13

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Irene L Wapnir, James J Dignam, Bernard Fisher, Eleftherios P Mamounas, Stewart J Anderson, Thomas B Julian, Stephanie R Land, Richard G Margolese, Sandra M Swain, Joseph P Costantino,[...]. J Natl Cancer Inst 2011
443
13

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
268
13

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
205
11


Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Jack Cuzick, Jane Warwick, Elizabeth Pinney, Stephen W Duffy, Simon Cawthorn, Anthony Howell, John F Forbes, Ruth M L Warren. J Natl Cancer Inst 2011
275
11

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Steven A Narod, Javaid Iqbal, Vasily Giannakeas, Victoria Sopik, Ping Sun. JAMA Oncol 2015
320
11

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
C Correa, P McGale, C Taylor, Y Wang, M Clarke, C Davies, R Peto, N Bijker, L Solin, S Darby. J Natl Cancer Inst Monogr 2010
383
11

A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene.
Silvia Noonan, Ambra Pasa, Vincenzo Fontana, Silvia Caviglia, Bernardo Bonanni, Alberto Costa, Samuel G Smith, Fedro Peccatori, Andrea DeCensi. Cancer Prev Res (Phila) 2018
15
46

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Anabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, Dirk Jan A R Moes, Stefan Böhringer, Erdogan Batman, Edith van Druten, Carolien Smorenburg, Aart van Bochove, Anneke Zeillemaker,[...]. J Clin Oncol 2019
51
13

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
John F Forbes, Ivana Sestak, Anthony Howell, Bernardo Bonanni, Nigel Bundred, Christelle Levy, Gunter von Minckwitz, Wolfgang Eiermann, Patrick Neven, Michael Stierer,[...]. Lancet 2016
91
10

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Richard G Margolese, Reena S Cecchini, Thomas B Julian, Patricia A Ganz, Joseph P Costantino, Laura A Vallow, Kathy S Albain, Patrick W Whitworth, Mary E Cianfrocca, Adam M Brufsky,[...]. Lancet 2016
92
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
L S Donnelly, D G Evans, J Wiseman, J Fox, R Greenhalgh, J Affen, I Juraskova, P Stavrinos, S Dawe, J Cuzick,[...]. Br J Cancer 2014
60
10

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
B Fisher, J Dignam, N Wolmark, D L Wickerham, E R Fisher, E Mamounas, R Smith, M Begovic, N V Dimitrov, R G Margolese,[...]. Lancet 1999
708
8


A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
684
8

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
126
8

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
Andrea Decensi, Sara Gandini, Davide Serrano, Massimiliano Cazzaniga, Maria Pizzamiglio, Fausto Maffini, Giuseppe Pelosi, Cristina Daldoss, Umberto Omodei, Harriet Johansson,[...]. J Clin Oncol 2007
54
11

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
8


Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Erika A Waters, Timothy S McNeel, Worta McCaskill Stevens, Andrew N Freedman. Breast Cancer Res Treat 2012
105
8

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill,[...]. Lancet 2013
8

RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.
Beryl McCormick, Kathryn Winter, Clifford Hudis, Henry Mark Kuerer, Eileen Rakovitch, Barbara L Smith, Nour Sneige, Jennifer Moughan, Amit Shah, Isabelle Germain,[...]. J Clin Oncol 2015
227
8

Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
58
10

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
Andrea Decensi, Chris Robertson, Giuseppe Viale, Francesca Pigatto, Harriet Johansson, Elton R Kisanga, Paolo Veronesi, Rosalba Torrisi, Massimiliano Cazzaniga, Serena Mora,[...]. J Natl Cancer Inst 2003
156
7

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
438
7


Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
7

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
150
7

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Aliana Guerrieri-Gonzaga, Ivana Sestak, Matteo Lazzeroni, Davide Serrano, Nicole Rotmensz, Massimiliano Cazzaniga, Clara Varricchio, Giancarlo Pruneri, Maria Cristina Leonardi, Roberto Orecchia,[...]. Int J Cancer 2016
20
25

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, Lisa M McShane, Fabrice Andre, Deborah E Collyar, Ana M Gonzalez-Angulo, Elizabeth H Hammond, Nicole M Kuderer, Minetta C Liu, Robert G Mennel,[...]. J Clin Oncol 2016
479
7

Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Brenda Deyarmin, Jennifer L Kane, Allyson L Valente, Ryan van Laar, Christopher Gallagher, Craig D Shriver, Rachel E Ellsworth. Ann Surg Oncol 2013
88
7

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
866
7

The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia Bennett, Celia Kaplan, Shoshana Rosenberg,[...]. BMJ Open 2019
94
7

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Sharon L Bober, Lizbeth A Hoke, Rosemary B Duda, Meredith M Regan, Nadine M Tung. J Clin Oncol 2004
111
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.